Ainos, Inc., an innovative healthcare company focused on advanced artificial intelligence (AI)-driven point-of-care testing (POCT) and low-dose interferon therapeutics, has announced the signing of a strategically significant Memorandum of Understanding (MoU) with Taiwan Tanabe Seiyaku Co., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, bringing extensive pharmaceutical development and manufacturing expertise to the partnership.

The collaboration aims to advance the manufacturing and Taiwan market promotion of Ainos' groundbreaking Sjögren's syndrome drug, VELDONA. Both parties may work under the terms of the MoU to further define the partnership.

Sjögren's syndrome is an autoimmune disease affecting millions of patients worldwide, with a significant unmet need for effective treatments. As the global population ages and awareness of the disease increases, the demand for therapeutic solutions is growing rapidly. According to market analysis, the global Sjögren's syndrome market is projected to reach billions of dollars in the next five years. Ainos believes VELDONA will provide a much-needed, innovative treatment option for millions of patients and fulfill this pressing market demand. 

This collaboration with Taiwan Tanabe Seiyaku will accelerate the global market introduction of VELDONA, ensuring that the drug reaches patients in a timely and efficient manner. The formal contract will define the clear rights and responsibilities of both parties, paving the way for long-term success.